Table 3.
Results of univariate and multivariate analysis influencing progression‐free survival
| n (%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | ||
| Age | |||||
| ≥75 | 7 (17.1) | .537 | |||
| <75 | 34 (82.9) | ||||
| PS | |||||
| 1,2 | 7 (17.1) | .119 | |||
| 0 | 34 (82.9) | ||||
| Visceral metastasis | |||||
| Yes | 12 (29.3) | .186 | |||
| No | 29 (70.7) | ||||
| PSA (ng/mL) | |||||
| >100 | 22 (53.7) | .001 | |||
| ≤100 | 19 (46.3) | ||||
| Hb (mg/dL) | |||||
| ≤11 | 17 (41.5) | .009 | |||
| >11 | 24 (58.5) | ||||
| NLR | |||||
| ≤3.8 | 20 (48.8) | .063 | |||
| >3.8 | 21 (51.2) | ||||
| ALP (U/L) | |||||
| >350 | 16 (39.0) | .003 | 3.91 | 1.52‐10.03 | .005 |
| ≤350 | 25 (61.0) | ||||
| Cabazitaxel starting dose (mg/m2) | |||||
| >20 | 27 (65.9) | <.001 | 0.40 | 0.18‐0.91 | .028 |
| 20 | 14 (34.1) | ||||
| Grade 3/4 neutropenia | |||||
| No | 19 (46.3) | .029 | |||
| Yes | 22 (53.7) | ||||
ALP, alkaline phosphatase; CI, confidence interval; HR, hazard ratio; NLR, neutrophil‐lymphocyte ratio; PS, performance status; PSA, prostate‐specific antigen.